Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.Submission of Matters to a Vote of Security Holders.
Blueprint Medicines Corporation (the “Company”) held its annual meeting of stockholders on June 20, 2018.The following is a summary of the matters voted on at the meeting.
1. |
The Company’s stockholders elected Daniel S. Lynch, George D. Demetri, M.D. and Lynn Seely, M.D. as Class III directors, each to serve until the 2021 annual meeting of stockholders and until his or her successor has been duly elected and qualified.The results of the stockholders’ vote with respect to the election of such Class III directors were as follows: |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Daniel S. Lynch |
32,852,065 | 6,048,688 | 2,467,641 |
George D. Demetri, M.D. |
32,196,702 | 6,704,051 | 2,467,641 |
Lynn Seely, M.D. |
33,062,895 | 5,837,858 | 2,467,641 |
2. |
The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows: |
Votes For |
Votes Against |
Votes Abstaining |
Broker Non-Votes |
38,403,708 | 492,764 | 4,281 | 2,467,641 |
3. |
The Company’s stockholders determined that future advisory votes on the compensation paid to its named executive officers would be held every year. The results of the stockholders’ non-binding, advisory vote with respect to the frequency of future advisory votes on the compensation paid to the Company’s named executive officers were as follows: |
1 Year |
2 Years |
3 Years |
Votes Abstaining |
BrokerNon-Votes |
38,805,413 | 2,111 | 91,145 | 2,084 | 2,467,641 |
After taking into consideration the foregoing voting results and the prior recommendation of the Company’s Board of Directors (the “Board”) in favor of an annual stockholder advisory vote on the compensation of the Company’s named executive officers, the Board intends to hold future advisory votes on the compensation of the Company’s named executive officers every year.
4. |
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting for the fiscal year ending December 31, 2018. The results of the stockholders’ vote with respect to such ratification were as follows: |
Votes For |
Votes Against |
Votes Abstaining |
41,340,067 | 7,941 | 20,386 |